|
Dr. Mark Swanson is an accomplished scientist with fifteen years of industrial science experience who has managed major CRO programs for large pharmaceutical and biotechnology companies. Dr. Swanson joins Gel Med from DNX Transgenic Sciences where he served as the Vice President of Transgenic Sciences. At DNX, he was responsible for directing the development of genetic related products and services to the pharmaceutical and biotechnology industry and was responsible for the overall management of DNX Transgenic Science’s contract research business. Prior to DNX, Dr. Swanson was a senior scientist at Sandoz Pharmaceutical Corporation (Novartis) and was involved in preclinical drug development. He received his Ph.D. (1983) in Molecular Biology and Biochemistry from the University of Connecticut Health Center and postdoctoral training at Columbia University/Howard Hughes Medical Institute (1983-1987). | 